Subset of Suz12/PRC2 target genes is activated during hepatitis B virus replication and liver carcinogenesis associated with HBV X protein

Chronic hepatitis B virus (HBV) infection is a major risk factor for developing liver cancer, and the HBV X protein (pX) has been implicated as a cofactor in hepatocyte transformation. We have shown that HBV replication as well as in vitro transformation by pX are associated with induction of the mitotic polo‐like kinase 1 (Plk1) and down‐regulation of the chromatin remodeling components Suz12 and Znf198. Herein, we demonstrate the same inverse relationship between Plk1 and Suz12/Znf198 in liver tumors from X/c‐myc bitransgenic mice and woodchuck hepatitis virus (WHV)‐infected woodchucks. Employing these animal models and the HBV replicating HepAD38 cells we examined the effect of Suz12/Znf198 down‐regulation on gene expression. Genes analyzed include hepatic cancer stem cell markers BAMBI, DKK1,2, DLK1, EpCAM, MYC, and proliferation genes CCNA1, CCND2, IGFII, MCM4‐6, PLK1, RPA2, and TYMS. Suz12 occupancy at the promoters of BAMBI, CCND2, DKK2, DLK1, EpCAM, and IGFII was demonstrated by chromatin immunoprecipitation in untransformed hepatocytes, but was markedly reduced in pX‐transformed and Suz12 knockdown cells. Accordingly, we refer to these genes as “Suz12 repressed” genes in untransformed hepatocytes. The Suz12 repressed genes and proliferation genes were induced in HBV‐replicating HepAD38 cells and, interestingly, they exhibited distinct expression profiles during hepatocellular carcinoma (HCC) progression in X/c‐myc bitransgenics. Specifically, CCND2, EpCAM, and IGFII expression was elevated at the proliferative and preneoplastic stages in X/c‐myc bitransgenic livers, whereas BAMBI and PLK1 were overexpressed in hepatic tumors from X/c‐myc bitransgenics and WHV‐infected woodchucks. Importantly, most of these genes were selectively up‐regulated in HBV‐induced HCCs. Conclusion: The distinct expression profile of the identified Suz12 repressed genes in combination with the proliferation genes hold promise as biomarkers for progression of chronic HBV infection to HCC. (HEPATOLOGY 2012)

[1]  A. Mes-Masson,et al.  H3K27 demethylation by JMJD3 at a poised enhancer of anti‐apoptotic gene BCL2 determines ERα ligand dependency , 2011, The EMBO journal.

[2]  Derek Y. Chiang,et al.  MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. , 2011, Gastroenterology.

[3]  K. Helin,et al.  The H3K27me3 demethylase, KDM6B, is induced by Epstein–Barr virus and over-expressed in Hodgkin's Lymphoma , 2011, Oncogene.

[4]  O. Andrisani,et al.  Proteins ZNF198 and SUZ12 are down‐regulated in hepatitis B virus (HBV) X protein‐mediated hepatocyte transformation and in HBV replication , 2011, Hepatology.

[5]  O. Andrisani,et al.  Gene signatures in hepatocellular carcinoma (HCC). , 2011, Seminars in cancer biology.

[6]  Toshiro K. Ohsumi,et al.  Genome-wide identification of polycomb-associated RNAs by RIP-seq. , 2010, Molecular cell.

[7]  K. Struhl,et al.  Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. , 2010, Molecular cell.

[8]  Howard Y. Chang,et al.  Long Noncoding RNA as Modular Scaffold of Histone Modification Complexes , 2010, Science.

[9]  Gregory F Weber,et al.  Polo-like Kinase 1 Activated by the Hepatitis B Virus X Protein Attenuates Both the DNA Damage Checkpoint and DNA Repair Resulting in Partial Polyploidy* , 2010, The Journal of Biological Chemistry.

[10]  Richard A Young,et al.  Short RNAs are transcribed from repressed polycomb target genes and interact with polycomb repressive complex-2. , 2010, Molecular cell.

[11]  Juri Rappsilber,et al.  JARID2 regulates binding of the Polycomb repressive complex 2 to target genes in ES cells , 2010, Nature.

[12]  C. Cavard,et al.  EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. , 2010, Journal of hepatology.

[13]  John Yu,et al.  Epithelial Cell Adhesion Molecule Regulation Is Associated with the Maintenance of the Undifferentiated Phenotype of Human Embryonic Stem Cells* , 2010, The Journal of Biological Chemistry.

[14]  Robert E. Kingston,et al.  Mechanisms of Polycomb gene silencing: knowns and unknowns , 2009, Nature Reviews Molecular Cell Biology.

[15]  S. Cairo,et al.  Polo‐like kinase 1 inhibition suppresses hepatitis B virus X protein‐induced transformation in an in vitro model of liver cancer progression , 2009, Hepatology.

[16]  X. Wang,et al.  EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. , 2009, Gastroenterology.

[17]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[18]  G. Grégori,et al.  Hepatitis B Virus X Protein Increases the Cdt1-to-Geminin Ratio Inducing DNA Re-replication and Polyploidy* , 2008, Journal of Biological Chemistry.

[19]  J. Bruix,et al.  Molecular targeted therapies in hepatocellular carcinoma , 2008, Hepatology.

[20]  Hongtao Yu,et al.  ZNF198 Stabilizes the LSD1–CoREST–HDAC1 Complex on Chromatin through Its MYM-Type Zinc Fingers , 2008, PloS one.

[21]  O. Andrisani,et al.  Hepatitis B Virus X Protein via the p38MAPK Pathway Induces E2F1 Release and ATR Kinase Activation Mediating p53 Apoptosis* , 2008, Journal of Biological Chemistry.

[22]  A. Hoffman,et al.  CTCF Regulates Allelic Expression of Igf2 by Orchestrating a Promoter-Polycomb Repressive Complex 2 Intrachromosomal Loop , 2008, Molecular and Cellular Biology.

[23]  Péter Lénárt,et al.  Polo on the Rise-from Mitotic Entry to Cytokinesis with Plk1. , 2008, Developmental cell.

[24]  Jin Woo Kim,et al.  EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. , 2008, Cancer research.

[25]  T. Jenuwein,et al.  Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. , 2007, Cancer cell.

[26]  Péter Lénárt,et al.  BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo , 2007, Current Biology.

[27]  P. Cote,et al.  The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection. , 2007, World journal of gastroenterology.

[28]  S. Boyault,et al.  Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets , 2007, Hepatology.

[29]  Henriette O'Geen,et al.  Suz12 binds to silenced regions of the genome in a cell-type-specific manner. , 2006, Genome research.

[30]  Kristian Helin,et al.  Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. , 2006, Genes & development.

[31]  F. Zoulim,et al.  A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine , 2006, Journal of viral hepatitis.

[32]  Ding‐Shinn Chen,et al.  Molecular genetic evidence supporting a novel human hepatocellular carcinoma tumor suppressor locus at 13q12.11 , 2005, Genes, chromosomes & cancer.

[33]  Duonan Yu,et al.  Functional Validation of Genes Implicated in Lymphomagenesis: An in Vivo Selection Assay Using a Myc‐Induced B‐Cell Tumor , 2005, Annals of the New York Academy of Sciences.

[34]  P. Schirmacher,et al.  Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade – results of an explorative CGH meta-analysis , 2005, British Journal of Cancer.

[35]  J. Jacob,et al.  Hepatocellular carcinoma in the woodchuck model of hepatitis B virus infection. , 2004, Gastroenterology.

[36]  Kai Breuhahn,et al.  Molecular Profiling of Human Hepatocellular Carcinoma Defines Mutually Exclusive Interferon Regulation and Insulin-Like Growth Factor II Overexpression , 2004, Cancer Research.

[37]  S. Thorgeirsson,et al.  Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling , 2004, Hepatology.

[38]  M. Buendia,et al.  Integration of woodchuck hepatitis and N‐myc rearrangement determine size and histologic grade of hepatic tumors , 2004, Hepatology.

[39]  J. Bruix,et al.  Focus on hepatocellular carcinoma. , 2004, Cancer cell.

[40]  D. Botstein,et al.  Gene expression patterns in human liver cancers. , 2002, Molecular biology of the cell.

[41]  Sook Y. Lee,et al.  Hepatitis B Virus X Protein Differentially Regulates Cell Cycle Progression in X-transforming Versus Nontransforming Hepatocyte (AML12) Cell Lines* , 2002, The Journal of Biological Chemistry.

[42]  B. Slagle,et al.  Hepatitis B Virus X Protein Acts as a Tumor Promoter in Development of Diethylnitrosamine-Induced Preneoplastic Lesions , 2001, Journal of Virology.

[43]  R. Purcell,et al.  Effects of age and viral determinants on chronicity as an outcome of experimental woodchuck hepatitis virus infection , 2000, Hepatology.

[44]  J. V. van Krieken,et al.  Expression of Ep‐CAM in normal, regenerating, metaplastic, and neoplastic liver , 1999, The Journal of pathology.

[45]  C. Tarn,et al.  Differential Immediate Early Gene Expression in Conditional Hepatitis B Virus pX-transforming Versus Nontransforming Hepatocyte Cell Lines* , 1999, The Journal of Biological Chemistry.

[46]  M. Otto,et al.  Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication , 1997, Antimicrobial agents and chemotherapy.

[47]  F. Zoulim,et al.  Woodchuck hepatitis virus-induced carcinoma as a relevant natural model for therapy of human hepatoma. , 1997, Journal of hepatology.

[48]  M. Buendia,et al.  The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice , 1997, Oncogene.

[49]  B. Ames,et al.  Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[50]  William McGinnis,et al.  Molecular cloning and chromosome mapping of a mouse DNA sequence homologous to homeotic genes of drosophila , 1984, Cell.

[51]  Lu-Yu Hwang,et al.  HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS A Prospective Study of 22 707 Men in Taiwan , 1981, The Lancet.